Clinical Trials Using Vemurafenib
Clinical trials are research studies that involve people. The clinical trials on this list are studying Vemurafenib. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
Pediatric MATCH: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders
This screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and / or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas.
Location: 42 locations
Pediatric MATCH: Vemurafenib in Treating Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders with BRAF V600 Mutations
This phase II trial studies how well vemurafenib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with BRAF V600 mutations that have spread to other places in the body and have come back or do not respond to treatment. Vemurafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Location: 37 locations
My Pathway: A Study Evaluating Herceptin / Perjeta, Tarceva, Zelboraf / Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors for whom therapies that will convey clinical benefit are not available and / or are not suitable options per the treating physician's judgment.
Location: 17 locations
Vemurafenib in Treating Children and Young Adults with Recurrent or Refractory BRAFV600E or BRAF Ins T Mutant Brain Tumors
This pilot early phase I trial tests the safety and side effects of the adult dose of vemurafenib in treating children and young adults with BRAFV600E or BRAF Ins T mutant brain tumors that have come back or do not respond to treatment. Vemurafenib may stop the growth of tumor cells by blocking some of the enzymes that tumors with this mutation need for growth.
Location: 16 locations
PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas
The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered intravenously (IV) as a single agent or in combination with ipilimumab or vemurafenib in adult subjects with advanced or recurrent solid tumors or lymphomas. PROCLAIM-CX-072: PRObody CLinical Assessment In Man CX-072 clinical trial CX-072 is a Probody™ therapeutic directed against PD-L1 (programmed cell death ligand 1). Probody therapeutics are proteolytically-activatable antibodies (Abs) designed to widen the therapeutic index by minimizing drug interaction with normal tissue while retaining anti-tumor activity. Probody therapeutics are "masked" to attenuate binding to target in healthy tissue but can become "unmasked" in the tumor microenvironment by tumor-specific protease activity. PROBODY is a trademark of CytomX Therapeutics, Inc.
Location: 14 locations
A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Participants With Metastatic or Unresectable Locally Advanced Melanoma
This is a Phase III, double-blinded, placebo-controlled, randomized, multicenter study designed to evaluate the efficacy, safety, and pharmacokinetics of combination of atezolizumab (ATZ), cobimetinib and vemurafenib compared with combination of ATZ placebo, cobimetinib and vemurafenib in participants with previously untreated BRAFv600 mutation-positive metastatic or unresectable locally advanced melanoma.
Location: 4 locations
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact TAPUR@asco.org, or if a patient, your nearest participating TAPUR site (see participating centers).
Location: 4 locations
An Extension (Rollover) Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol
This open-label, multicenter, non-randomized study will provide continued access to vemurafenib for eligible participants with BRAF V600 mutation-positive malignancy, who were previously enrolled and treated in an antecedent vemurafenib protocol and did not meet the protocol's criteria for disease progression, or are treated beyond progression and are still deriving clinical benefit (as assessed by investigator), and may therefore potentially benefit from continued treatment with vemurafenib. Participants will receive treatment with oral vemurafenib at 960 milligrams (mg) twice daily (BID), 720 mg BID, or 480 mg BID, depending on the last dose in the antecedent protocol. Treatment will continue until progression of disease or as long as the participant is deriving clinical benefit, as judged by the investigator (case-by-case decision with approval of the Medical Monitor), death, withdrawal of consent, unacceptable toxicity, loss to follow-up, or decision of the Sponsor to terminate the study, whichever occurs first.
Location: 4 locations
Anti-CSF1R Monoclonal Antibody IMC-CS4, Vemurafenib, and Cobimetinib in Treating Patients with Melanoma That is Metastatic or Cannot Be Removed by Surgery
This phase I / II trial studies the side effects and best dose of anti-CSF1R monoclonal antibody IMC-CS4 when given together with vemurafenib and cobimetinib and to see how well they work in treating patients with melanoma that has spread to other places in the body or cannot be removed by surgery. Monoclonal antibodies, such as nti-CSF1R monoclonal antibody IMC-CS4, may interfere with the ability of tumor cells to grow and spread. Vemurafenib and cobimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving anti-CSF1R monoclonal antibody IMC-CS4, vemurafenib, and cobimetinib may work better in treating patients with melanoma.
Location: 2 locations
Vemurafenib and Pembrolizumab in Treating Stage III-IV Melanoma That Cannot Be Removed by Surgery
This phase I / II trial studies the side effects and best dose of vemurafenib and to see how well it works when given together with pembrolizumab in treating stage III-IV melanoma that cannot be removed by surgery. Vemurafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as pembrolizumab, may block tumor growth in different ways by targeting certain cells. Giving vemurafenib and pembrolizumab together may work better in treating patients with stage III-IV melanoma that cannot be removed by surgery.
Location: 2 locations
Vemurafenib and Cobimetinib in Treating Patients with BRAF V600E Mutation Positive Craniopharyngioma
This phase II trial studies how well vemurafenib and cobimetinib work in treating patients with BRAF V600E mutation positive craniopharyngioma. Vemurafenib and cobimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Location: Alliance for Clinical Trials in Oncology, Boston, Massachusetts
Hsp90 Inhibitor XL888, Vemurafenib, and Cobimetinib in Treating Patients with BRAF Mutated Stage IIIB-IV Melanoma That Cannot Be Removed by Surgery
This phase I trial studies the side effects and best dose of hsp90 inhibitor XL888 when given with vemurafenib and cobimetinib in treating patients with BRAF mutated stage IIIB-IV melanoma that cannot be removed by surgery. Hsp90 inhibitor XL888, vemurafenib, and cobimetinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Location: Moffitt Cancer Center, Tampa, Florida
A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State
This is a two-part, Phase 1, open-label, multicenter, two-period, one-sequence study to investigate the effect of itraconazole and rifampin on the PK of vemurafenib following multiple 960 milligrams (mg) twice daily (BID) dosing in adult participants with unresectable Stage IIIC or Stage IV metastatic melanoma positive for the BRAF V600 mutation, or other malignant tumor types that harbor a V600-activating mutation of BRAF where the participant has no acceptable standard treatment options.
Location: University of Kansas Cancer Center, Kansas City, Kansas
Vemurafenib and Recombinant Interferon alfa-2b in Treating Patients With Stage III-IV Melanoma
This phase I trial studies the side effects and best dose of vemurafenib when given together with recombinant interferon alfa-2b in treating patients with stage III-IV melanoma. Vemurafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Recombinant interferon alfa-2b may interfere with the growth of tumor cells and slow the growth of melanoma. Giving vemurafenib and IFN alfa-2b may be an effective treatment for melanoma.
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Decitabine, Vemurafenib, and Cobimetinib in Treating Patients with Stage IV Melanoma Who Have a BRAF Mutation
This phase I / II trial studies the side effects and best dose of decitabine when given together with vemurafenib and cobimetinib and to see how well it works in treating patients with melanoma that has spread to other parts of the body and who have a mutation in a gene called v-raf murine sarcoma viral oncogene homolog B1(BRAF). BRAF is a gene that can cause the growth and spread of tumor cells. Decitabine, vemurafenib, and cobimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth, including enzymes from the BRAF gene. Giving decitabine, vemurafenib, and cobimetinib together may improve response compared with vemurafenib alone in patients with BRAF-mutated melanoma.
Location: University of Iowa / Holden Comprehensive Cancer Center, Iowa City, Iowa
Vemurafenib with Sorafenib Tosylate or Crizotinib in Treating Patients with Advanced Malignancies with BRAF Mutations
This phase I clinical trial studies vemurafenib with sorafenib tosylate or crizotinib in treating patients with advanced malignancies with BRAF mutations. Sorafenib tosylate and crizotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Sorafenib tosylate may also stop the growth of advanced malignancies by blocking blood flow to tumors. Drugs used in chemotherapy, such as vemurafenib, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving vemurafenib together with sorafenib tosylate or crizotinib may kill more cancer cells.
Location: M D Anderson Cancer Center, Houston, Texas
Leflunomide and Vemurafenib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed By Surgery
This phase I / II trial studies the side effects and best dose of leflunomide when given together with vemurafenib and to see how well they work in treating patients with melanoma that is metastatic or cannot be removed by surgery. Leflunomide and vemurafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Location: Massachusetts General Hospital, Charlestown, Massachusetts
Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation
- An Open Label, Multicenter, Phase I Extension Study of an Oral Cdk Inhibitor P1446A-05 Administered with an Oral BRAF Inhibitor Vemurafenib (Zelboraf®) in Patients with Advanced or Inoperable Malignant Melanoma with BRAF Mutation - The primary objective is to determine the safety, maximum tolerated dose (MTD), and dose limiting toxicity (DLT) of the co-administration of P1446A-05 with vemurafenib, in melanoma patients with BRAF mutation
Location: See Clinical Trials.gov